• NICE recommends Merck’s erbitux to treat R/M SCCHN in oral cavity pharmaceutical-technology
    August 11, 2017
    The UK National Institute for Health and Care Excellence (NICE) has recommended the routine use of Merck’s erbitux (cetuximab), in combination with platinum-based chemotherapy, to treat recurrent and / or metastatic (R/M) squamous cell carcinoma of the he
PharmaSources Customer Service